Janssen submits hepatitis C drug candidate Simeprevir for FDA approval

04/2/2013 | Pharmaceutical Business Review Online

Janssen Research & Development filed a new drug application with the FDA for approval to use its NS3/4A protease inhibitor Simeprevir, or TMC435, with pegylated interferon and ribavirin as a treatment for genotype 1 chronic hepatitis C. The application was based on results of late-stage trials involving previously untreated and treatment-experienced patients with compensated liver disease.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ
Director, Payer Marketing
Avalere Health
Washington, DC
Director of Utilization Management
Meridian Health Plan
Chicago, IL
Senior Manager, Healthcare Reform
Avalere Health
Washington, DC